NASDAQ
Alnylam Pharmaceuticals, Inc. (ALNY)
♥ 307 Thanks from members
Alnylam Pharmaceuticals (ALNY) experienced a 25% stock tumble following a Q2 2026 revenue miss and full-year guidance cut for AMVUTTRA, though management underscores strong underlying first-line demand and favorable competitor failures.